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Abstract
Background: Chronic subdural haematoma (CSDH) is a common neurosurgical condition, typically treated with
surgical drainage of the haematoma. However, surgery is associated with mortality and morbidity, including up to
20% recurrence of the CSDH. Steroids, such as dexamethasone, have been identified as a potential therapy for
reducing recurrence risk in surgically treated CSDHs. They have also been used as a conservative treatment
option, thereby avoiding surgery altogether. The hypothesis of the Dex-CSDH trial is that a two-week course of
dexamethasone in symptomatic patients with CSDH will lead to better functional outcome at six months. This is
anticipated to occur through reduced number of hospital admissions and surgical interventions.
Methods: Dex-CSDH is a UK multi-centre, double-blind randomised controlled trial of dexamethasone versus
placebo for symptomatic adult patients diagnosed with CSDH. A sample size of 750 patients has been determined,
including an initial internal pilot phase of 100 patients to confirm recruitment feasibility. Patients must be recruited
within 72 h of admission to a neurosurgical unit and exclusions include patients already on steroids or with steroid
contraindications, patients who have a cerebrospinal fluid shunt and those with a history of psychosis. The decision
regarding surgical intervention will be made by the clinical team and patients can be included in the trial
regardless of whether operative treatment is planned or has been performed. The primary outcome measure
is the modified Rankin Scale (mRS) at six months. Secondary outcomes include the number of CSDH-related
surgical interventions during follow-up, length of hospital stay, mRS at three months, EQ-5D at three and six
months, adverse events, mortality and a health-economic analysis.
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Discussion: This multi-centre trial will provide high-quality evidence as to the effectiveness of dexamethasone
in the treatment of CSDH. This has implications for patient morbidity and mortality as well as a potential
economic impact on the overall health service burden from this condition.
Trial registration: ISRCTN, ISRCTN80782810. Registered on 7 November 2014. EudraCT, 2014-004948-35.
Registered on 20 March 2015.
Dex-CSDH trial protocol version 3, 27 Apr 2017.
This protocol was developed in accordance with the SPIRIT checklist. Available as a separate document on
request.
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Background
Chronic subdural haematoma (CSDH) is an ‘old’ collec-
tion of blood and blood breakdown products in the sub-
dural space. It is radiologically defined as a predominantly
hypodense or isodense collection in the subdural space
along the cerebral convexity on computed tomography
(CT). It is especially common in older patients and in the
UK, 5000 people aged > 65 years are diagnosed with a
CSDH each year. It can happen following only a minor
injury to the head or even in the absence of a known
trauma [1]. Symptoms that can be attributed to a CSDH
include headache, gait disturbance, falls, cognitive decline,
focal neurological deficit, speech disturbance, decreased
consciousness and seizures.
Patients with severe symptoms usually undergo an oper-
ation to evacuate the CSDH; while around 80% of patients
recover well, around 10–20% experience recurrence of the
CSDH requiring further surgery [1, 2]. Evidence from a
previous CSDH trial looking at subdural drains demon-
strated that a reduction in recurrence resulted in reduced
mortality and rate of poor functional outcome at six
months [1]. A considerable body of evidence suggests that
administration of steroids could reduce CSDH recurrence
and even the rate of primary surgical intervention [2–5].
This, in turn, might be expected to reduce mortality and
morbidity and improve long-term functional outcome in
patients with CSDH. While the mechanism of action of
steroids in CSDH is not entirely understood, recent re-
search suggests that inflammation may be responsible for
driving the continued growth of CSDH [6–9]; therefore,
steroids may help overcome this.
The Dex-CSDH trial (DEXamethasone in Chronic Sub-
Dural Haematoma) is a multi-centre, pragmatic, clinical
phase III, randomised, double-blind, placebo-controlled
trial of dexamethasone for up to two weeks in patients di-
agnosed with CSDH. Dexamethasone is one of the most
potent synthetic analogues of the naturally occurring
glucocorticoid hydrocortisone and has practically no
water- and salt-retaining properties, so is suitable for use
in patients with cardiac failure or hypertension [10]. The
earliest application of steroids in neurosurgery was for pa-
tients with brain tumours and surrounding oedema, where
4mg four times a day was established as the dose with
maximum effect [11]. This dosing, with subsequent grad-
ual weaning, continues to be used in neuro-oncology and
a two-week course of dexamethasone was considered
likely to provide the best balance in terms of clinical effi-
cacy and risks in this study [12]. The dose and duration
are also reflective of other studies in the field [13].
The potential impact of this trial is significant, as
the results will determine whether steroids should be
prescribed routinely for patients with symptomatic
CSDH. If steroids are found to be effective, an impact
on the speed of recovery and functional outcome of
patients is expected. This will be measured by the pri-
mary outcome, the modified Rankin Scale (mRS) at
six months. Additionally, this could reduce the rate of
surgical interventions required, length of hospital stay,
discharge destination and adverse events (AEs). As
well as the impact on clinical outcome, there are
health economic considerations that will be addressed
by the trial.
Trial rationale
We hypothesise that a two-week course of dexametha-
sone can improve the six-month functional outcome of
patients with symptomatic CSDH by reducing the rate
of CSDH-related surgical interventions and the recur-
rence rate.
Trial objectives
Primary objective
To detect an 8% absolute difference in the rate of
favourable outcome at sixmonths between the two arms.
Secondary objectives
 Compare the long-term clinical effectiveness of dexa-
methasone versus placebo (six-month follow-up period)
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 Compare the AEs and complications between the
two arms
 Undertake a detailed economic evaluation between
the two arms
Exploratory (mechanistic) objectives
 Assess the biological action of dexamethasone with
CSDH fluid and blood analysis
 Assess the role of dexamethasone in cerebral
perfusion and swelling in CSDH
Methods
Study setting
All study sites are in the UK. Patients are admitted to
their local neurosurgical unit (NSU) following diagnosis
of CSDH on CT. Local clinical neurosurgical teams
review patients upon admission to the NSU and will
assess eligibility for the Dex-CSDH trial. The decision
for surgery or active monitoring is made on an individ-
ual patient basis by the admitting clinical team in con-
junction with the patient and their families. This will
not be affected by trial involvement, with both surgical
and conservatively managed patients eligible for trial
recruitment.
Eligibility criteria
Screening of patients to determine eligibility for partici-
pation in the trial will be undertaken by the neurosurgi-
cal team upon admission to the NSU according to the
following criteria.
Inclusion criteria
– Adult patients (aged ≥ 18 years)
– Symptomatic CSDH confirmed on cranial imaging
(e.g. CT/magnetic resonance imaging [MRI]),
predominantly hypodense or isodense crescentic
collection along the cerebral convexity on CT
– Informed consent or Independent healthcare
profession (IHP) authorisation
Exclusion criteria
– Patients with conditions where steroids are clearly
contraindicated
– Patients who are on (or within onemonth of) regular
oral or intravenous glucocorticoid steroids
– Previous enrolment in this trial for a prior episode
– Time interval from the time of the admission to the
NSU to the first dose of the investigational medicinal
product (IMP) > 72 h
– CSDH in the presence of a cerebrospinal fluid shunt
– Severe lactose intolerance or any known
hypersensitivity to dexamethasone or other IMP
excipients
– Patients with a previous history of psychotic disorders
– Unwillingness to take products containing gelatin
– Concurrent enrolment in any other trial of an IMP
– Biochemical sub-study only: active malignancy or
currently receiving immunosuppressive drug therapy
– MRI sub-study only: renal dysfunction, pacemaker or
metal implants
Interventions
The trial aims to run in parallel to standard clinical care.
The only difference between the trial pathway and the
standard NHS pathway is the addition of a two-week
tapering course of either dexamethasone or placebo
(as per Table 1).
The trial treatment can be delivered orally or by naso-
gastric tube. In special circumstances (such as patients
who are nil by mouth for surgery), where study medica-
tion is missed at lunchtime, that day’s dose(s) may be
taken later as long as it is on the same day. Otherwise,
in the event of missing a dose of medication, these can
be taken when remembered, but only up to the time of
the next planned dose on the same day. No dose modifi-
cations are permitted within this trial. The trial is being
carried out under a Clinical Trial Authorisation (CTA);
for a list of known drug reactions and interaction with
other therapies, see Appendix 1.
Irrespective of whether an operation is undertaken,
patients will complete the two-week course of trial
medication. Patients may be discharged or transferred
to a local hospital before the completion of the
two-week course; in this case, letters will be provided
to the patient and medical and pharmacy teams at the
local hospital along with the remaining trial medication
to ensure that the course is completed. The exception
to this will be in the event of a patient receiving study
drug via the nasogastric route, where it will be stopped
at discharge/ transfer if this is the case.
Trial teams will ensure compliance with treatment is
documented, using source data which should include the
inpatient medication administration record and the trial
medication diary, as well as performing physical capsule
counts during inpatient treatment where possible. Please
refer to the Dex-CSDH IMP Handling Manual for fur-
ther information.
Any concomitant therapy clinically required will be
permitted, including gastroprotection as per local policy.
A list of contraindicated concomitant therapies to be
avoided during the trial is detailed in sections 4.3 and
4.5 of the current SmPC for dexamethasone [14]. Only
concomitant therapies of interest will be recorded on
the concomitant medication log in the case report form
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(CRF), including: gastroprotection; anti-diabetic medica-
tion; and single (intraoperative) dose of dexamethasone.
Trial outcome measures
Primary outcome measure
mRS at six months after randomisation (Table 2). This
scale was selected as it is a core instrument for measur-
ing the degree of disability or dependence in daily activ-
ities of living and has previously been used in CSDH
studies and stroke research, which affects a similar pa-
tient demographic [1, 15, 16].
Secondary outcome measures
1. Number of CSDH-related surgical interventions
undertaken during the index admission
2. Number of CSDH-related surgical interventions
undertaken during subsequent admissions in the
follow-up period
3. Glasgow Coma Scale (GCS) at discharge from NSU
and at six months
4. mRS score at discharge from NSU and at threemonths
5. Barthel Index at discharge from NSU, three months
and six months
6. Mortality (at 30 days and six months)
7. EuroQOL (Quality of life) EQ-5D at discharge from
NSU, three months and six months.
8. Length of stay in NSU
9. Discharge destination from NSU
10. Length of stay in secondary care
11. Health-economic analysis
12. AEs
Economic evaluation
An economic analysis will be conducted alongside the
trial. Costs will be estimated from the viewpoint of the
NHS and personal social services. Resources associated
with provision of dexamethasone will thereby be moni-
tored along with any surgical operation(s) to evacuate
the CSDH, length of stay in NSU and any further hos-
pital admissions /surgical procedures, e.g. for recurrence
of the CSDH. Additionally, the level of informal care will
also be monitored to estimate the opportunity cost for
family, friends, carers and patients.
Exploratory (mechanistic) outcome measures
To assess the mechanism of action of dexamethasone,
we will be collecting CSDH fluid and blood samples on
selected patients who undergo surgery as part of their
standard clinical care. Analysis of inflammatory bio-
markers will be performed on blood and CSDH fluid
and compared between the dexamethasone and placebo
patients. Transcranial Doppler (TCD) and MRI may also
be used in a sub-set of patients to measure cerebral
blood flow patterns and assess whether this can be used
to predict recovery and recurrence from CSDH.
Participant timeline: trial assessments and schedule
All patients will have a medical history taken and a clinical
examination as part of the routine standard of care, includ-
ing: past medical history; injury-related events; neurological
status; imaging (modality, date of examination and original
images at selected sites); and routine lab results. Additional
data will be collected on the exploratory outcomes (CSDH
fluid, blood, TCD and MRI) if applicable, at the sponsor site
only. Full details are available in the DEX-CSDH Labora-
tory and Imaging Manuals. Figure 1 shows a full schedule
of trial assessments as per SPIRIT guidelines.
Sample size
A sample size of 750 patients was determined with a power
in the range of 81–92% and a two-sided significance of 5%,
allowing for 15% missing data.
Table 1 Trial dosing regimen
Day Capsules (n) Equivalent dexamethasone
dose
1, 2 and 3 4 in the morning, 4
at lunchtime
8mg BD = 16mg/day for
3 days
4, 5 and 6 3 in the morning, 3
at lunchtime
6mg BD = 12mg/day for
3 days
7, 8 and 9 2 in the morning, 2
at lunchtime
4mg BD = 8mg/day for
3 days
10, 11 and 12 1 in the morning, 1
at lunchtime
2mg BD = 4mg/day for
3 days
13 and 14 1 in the morning. 2 mg/day for 2 days
Total 62 capsules 124 mg over 14 days
Day 1 = day of first dose. Day 14 = last day of treatment. Day 1 treatment can
be given as 1 combined dose of 16mg (8 capsules) if needed, depending on
the time of day the treatment is commenced
BD twice a day
Table 2 Modified Rankin Scale (mRS)
mRS score Description
0 No symptoms at all
1 No significant disability despite symptoms; able to carry
out all usual duties and activities
2 Slight disability; unable to carry out all previous activities,
but able to look after own affairs without assistance
3 Moderate disability; requiring some help (e.g. with
shopping/managing affairs) but able to walk without
assistance
4 Moderately severe disability; unable to walk without
assistance and unable to attend to own bodily needs
without assistance
5 Severe disability; bedridden, incontinent and requiring
constant nursing care and attention
6 Dead
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Recruitment
The study commences with an internal pilot, stage 1
(feasibility study) to ensure 100 patients can be recruited
by a limited number of centres within 12 months.
Following successful completion of this, stage 2 (substan-
tive study) will take place. The recruitment rate has been
estimated at two patients per site per month. On the
basis of Hospital Episode Statistics (HES) and data from
the national CSDH audit [17], approximately 60–80
patients with a CSDH are admitted in a medium-sized
NSU each year. Hence, the estimated recruitment rate is
feasible. Patients will be monitored while in the acute
NSU and followed up for a period of six months after
recruitment.
Treatment assignment, randomisation and blinding
Patients will be randomly assigned to either the control
or intervention group with a 1:1 allocation as per a
computer-generated randomisation schedule stratified
by site using permuted blocks of random sizes. An inter-
active web-based response system (IWRS) will be used
for allocating treatment packs to individual patients once
confirmation that the inclusion criteria have been met
has been confirmed.
Placebo is a capsule, visually indistinguishable from
the active treatment and containing inactive excipients only.
Dexamethasone capsules will consist of over-encapsulated
dexamethasone 2mg tablets. A proprietary brand will be
used. The study drug will be supplied in individually num-
bered patient bottles. Capsules and packaging for both
active and placebo arms will be identical in appearance at
the point of issue to patients.
It is estimated that < 10% of eligible patients will have
(or develop during the trial) swallowing difficulties, mak-
ing oral IMP administration difficult or impossible/un-
safe. In such cases, the blinded capsules may be opened
at the point of administration by ward nursing staff and
the contents dispersed in water, for administration either
via oral route or a nasogastric tube. The administering
nurse and potentially the trial patient will no longer be
blinded, because the active dexamethasone is in tablet
form that has been over-encapsulated and the placebo
will be in powder form. To maintain blinding of the neu-
rosurgeons, the presence of tablets being inside the
Fig. 1 Schedule of assessments. * = only collected in patients recruited to sub-study in coordinating centre. Ax within 72 h of admission to NSU,
AE adverse event, D day, D/C discharge (or death if sooner), EQ-5D European Quality of life-5 dimensions, IMP investigational medicinal product,
I-O intraoperative, mon months, mRS modified Rankin Scale
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opened capsule should not be documented in the
medical notes.
Every effort must be made to maintain patient blinding
when NG administration is used, by the patient not see-
ing the capsules being opened. Should, despite these ef-
forts, the patient discover their treatment, they should
be asked to not disclose their treatment allocation to any
of the other medical personnel they interact with, e.g.
surgeons, etc. The research staff and outcome assessors
will remain blinded.
There are also clinical aspects that could potentially
unblind trial team members to treatments allocated.
Patients receiving dexamethasone will be more likely to
have higher blood glucose levels compared to those
receiving placebo. This may provide an indication but
not proof that a patient is in the active arm. Conceal-
ment of glucose measurements will be difficult as clin-
ical action may be required.
Any decision about surgery is made based on the
severity of symptoms and/or progression of symptoms.
Therefore, in cases where the IMP has been started be-
fore any neurosurgical intervention, a hint that the
patient is in the active arm would have little influence
on decisions about operative or non-operative manage-
ment. Overall, we anticipate this occurring in such a
small number of patients that the risk of bias is negli-
gible and will not affect the overall findings of the study.
Emergency unblinding
Emergency unblinding will be managed according to the
emergency unblinding procedure using the IWRS. Emer-
gency unblinding requested by the patient’s clinical team
will only occur in exceptional circumstances (e.g. need
to treat a serious adverse event [SAE]) when knowledge
of the actual treatment is essential for further manage-
ment of the patient.
Patient withdrawal
Each patient has the right to discontinue their participa-
tion in the trial at any time. If an unconscious patient
regains capacity and makes a request to be withdrawn
from the trial then this is accepted. Incapacitated
patients may also be withdrawn from the trial if the con-
sultee requests withdrawal. In addition, the investigator
may withdraw the patient from their allocated treatment
arm if, subsequent to randomisation, a clinical reason
for not providing the drug treatment is discovered.
As the trial will be analysed on an intention to treat basis,
any data collected will remain in the trial and the patient
will continue to be followed up unless consent is with-
drawn. Patients who have been withdrawn from the trial
will not be replaced as the power calculation for the trial al-
lows for a 15% loss to follow-up. All discontinuations and
withdrawals will be documented. If a patient wishes to dis-
continue, anonymised data collected up until that point will
be included in the analysis.
Consent, enrolment and data collection
All patients who have been admitted to the NSU with a
confirmed CSDH may be screened for eligibility. Screen-
ing will be carried out by a member of the clinical team
and a log kept. Consent must be taken before study ran-
domisation and study drug administration.
Where potential patients fulfil the eligibility criteria,
they will be approached by a member of the research
team who will provide the patient information sheet and
clarify any information from the patient/relatives which
may preclude recruitment. At Cambridge only, patients
will also be screened for eligibility for the exploratory
sub-studies. If they are eligible, they will be given an
additional page in the patient information and consent
sheet so that they can consider if they would like to take
part in any of the additional sub-studies. If they do not
wish to take part in these, it will not affect their recruit-
ment to the main trial.
Wherever possible, informed consent will be obtained
from the patient. However, due to the nature of the con-
dition, this may not always be possible. If lacking cap-
acity, patients with CSDH can still be enrolled in the
trial if consent is obtained from:
i. the patient’s legal representative (if available in
the hospital);
ii. IHP consent (if a patient’s legal representative is not
available in the hospital) - this can be completed by
someone who is not connected with the conduct of
the trial, specifically:
a. the sponsor of the trial;
b. a person employed or engaged by or acting
under the arrangements with the sponsor, and
who undertakes activities connected with the
management of the trial;
c. an investigator of the trial; or
d. a healthcare professional who is a member of the
investigators’ team for the purposes of the trial.
Patients who regain capacity will be informed about
the clinical trial and consent to continue will be sought
during their in-patient stay and if still lacking capacity
on discharge, at their six-month clinical follow-up
appointment (if attended). If at any stage either the legal
representative or the patient chose to withhold consent,
then the patient will be withdrawn from the trial.
All enrolled patients will be offered an optional study
wrist band, to be applied before their first dose of medi-
cation and worn while they are an inpatient. This high-
lights that they are taking part in a blinded study and
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helps the patient and nursing staff be aware of the study
at all times and to reduce the risk of open label ward
dexamethasone stocks being used in error.
Patients will be monitored as per routine clinical prac-
tice in the NSU until discharge and thereafter at approxi-
mately three and sixmonths to assess clinical outcome.
Follow-up will be by postal questionnaire. However, if
after two weeks the questionnaire has not been returned,
patients will be followed up by telephone. If after a further
four weeks there is no response, then the patient will be
deemed as lost to follow up. Where patients attend for a
routine clinical follow-up, they will be reviewed by a
blinded assessor.
Data management
A final trial report will be written for publication and
trial results will be presented internationally at meetings.
All data will be entered into a CRF, which will be anon-
ymised. The CRF will be accessible to trial coordinators,
data managers, the investigators, Clinical Trial Monitors,
Auditors and Inspectors as required. All CRF pages will
be completed in a Good Clinical Practice (GCP)-compli-
ant manner. All investigators and trial site staff involved
in this trial must comply with UK Data Protection
requirements and Trust Policy with regards to the col-
lection, storage, processing and disclosure of personal
information.
Statistical methods
Analysis will be performed on an ‘intention-to-treat’
basis. The primary endpoint is the mRS at six months
which is then dichotomised to favourable (0–3) versus
unfavourable (4–6). The primary analysis will estimate
the absolute difference between the two treatment arms
in the proportions achieving a favourable outcome. A
normal approximation will be used to produce 95% con-
fidence interval and a two-sided p value testing the null
hypothesis of no difference. Secondary analysis will
include a proportional odds logistic regression of the
mRS score adjusting for baseline covariates (age, GCS).
Assuming a favourable outcome rate of 80–85% in the
control group, an 8% increase in the rate of favourable
outcome (mRS 0–3) at six months is a plausible and
clinically important treatment effect [1]. Using a two-
sided test at the 5% significance level, a sample size of
750 patients (allowing for a 15% loss to follow-up) will
enable us to detect this 8% absolute difference in the
rate of favourable outcome with a power of 81–92%.
Further secondary endpoints will be summarised using
appropriate techniques according to whether the vari-
able is binary, categorical, continuous or time-to-event.
Categorical and binary variables will be summarised using
bar charts, frequency tables and comparisons made using
logistic regression. Continuous variables will be summarised,
broken down by treatment arm, using Box plots, mean, me-
dian, SD, max, min and compared using linear regression.
Time-to-event variables will be summarised using Kaplan–
Meier plots, and compared using the log-rank test.
Economic analysis
Appropriate unit costs will be assigned to each item
of the aforementioned items of resource use (see trial
outcome measures) using a standard price year. The
mean incremental cost for those allocated to dexa-
methasone compared to placebo intervention over the
six-month trial period will then be estimated, from
both an NHS and personal social services perspective,
and also with the addition of informal care costs.
Assuming dominance does not occur (where one
option is estimated to be more effective and less
costly that the other option), the incremental cost-ef-
fectiveness ratio associated with dexamethasone will
be estimated and assessed in relation to a range of
cost-effectiveness thresholds, e.g. £20,000–30,000 per
quality-adjusted life years (QALY) is recommended by
National Institute for Health and Care Excellence
(NICE) [18]. The associated level of uncertainty will
also be characterised by estimating cost-effectiveness
acceptability curves [19]. Additionally, sensitivity ana-
lysis will also be undertaken to assess the robustness
of conclusions to change in key assumptions. In line
with the outcome analysis, all analyses will initially be
conducted on an intention-to-treat basis.
Interim analysis
An interim analysis, blinded to all except the study’s
Independent Data Monitoring and Ethics Committee
(IDMEC), will be performed after an appropriate number
of patients have reached the six-month follow-up, to con-
firm the final sample size. The Trial Steering Committee
(TSC), IDMEC and statistical team will agree jointly on
the most appropriate timing of this interim analysis, tak-
ing into account the case mix and parameters the IDMEC
wishes to estimate. If the sample size needs to be revised,
we are able to incorporate the uncertainty in absolute
favourable outcomes rates (80–85%) in order to achieve
an acceptable conditional power as determined by the
IDMEC. If sample size adjustment is necessary, the final
analysis will adjust for the inflated type 1 error rate. The
primary purpose of the internal pilot (first 100 patients) is
to assess recruitment rates rather than to make sample
size adjustments.
There are no defined criteria for the premature discon-
tinuation of the trial. However, the IDMEC and TSC will
make recommendations on the discontinuation of the trial
following review of the ongoing patient safety and efficacy
data presented at regular scheduled meetings. For the pri-
mary analysis, missing data will be assumed to be missing
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at random. A sensitivity analysis will be carried out by
performing a complete case analysis. As the relevant
covariates need to be recorded before the patient can be
randomised, we aim to have minimal missing baseline
data. There is also an excellent track record for UK-led
neurosurgical studies in achieving extremely high rates for
follow-up [20–22].
The end of the trial is the date that the last expected
six-month follow-up questionnaire is completed for the
last-recruited trial patient.
Trial monitoring and safety
The TSC will provide overall supervision with respect to
the conduct of the trial and be independently chaired by
Professor Anthony Bell (St George’s, University of
London, London, UK). The ethical and safety aspects of
the trial will be overseen by an IDMEC, which will be
chaired by Professor Martin Smith (The National
Hospital for Neurology and Neurosurgery, London, UK).
The competent authority, the Medicines and Health-
care Products Regulatory Agency (MHRA), provided
clinical trials authorisation before trial commencement.
The protocol and trial conduct will comply with the
Medicines for Human Use (Clinical Trials) Regulations
2004 and any relevant amendments. Development Safety
Update Reports and Annual Safety Reports are submit-
ted to the MHRA in accordance with UK requirements.
It is the Chief Investigators responsibility to produce the
annual reports as required.
Due to the patient demography and the clinical condi-
tion of CSDH, there may be many AEs throughout the
initial admission. All patients are regularly monitored
either in the intensive care environment or on the neuro-
surgical wards, but it is not practicable to record all AEs.
Therefore, only AEs of special interest (AESIs) and SAEs
will be reported. Some SAEs will be classified as ‘expected’
and therefore exempt from expedited reporting, although
all will be recorded on a log (see Table 3). See Appendix 2
for a full list of AE descriptions and details.
Discussion
Despite the interest in, and potential impact of, conser-
vative treatment options for CSDH patients, there cur-
rently exists no level 1 evidence to support any drug
treatments. However, several studies have supported
the use of dexamethasone and shown some evidence of
its efficacy in reducing recurrence or as a primary treat-
ment for CSDH [3–5, 9]. As a result, some clinicians
are beginning to adopt dexamethasone as a treatment
option in their routine practice. Assimilation of such
new therapies into clinical care should be avoided until
definitive evidence is available. The reasoning for this is
exemplified by Prud’homme et al., who highlighted the
potential adverse side effects associated with dexametha-
sone therapy in this patient population [23]. Such findings
must be considered in trial design and it is evident that
proving whether a medication is effective is not sufficient.
One must also review the risk–benefit profile of a treat-
ment to ensure the overall outcome affords significant
benefit to the patient. Therefore, we have focused on func-
tional outcome measures (e.g. mRS), so that the overall
effect on quality of life, rather than change in imaging or
tissue biomarker, is used to gauge success. This can only
be achieved with a pragmatic, multi-centre trial, such as
Dex-CSDH. Understanding the cost implications of new
therapies is also important in NHS practice; therefore,
health-economic analysis has also been incorporated in
this trial protocol.
Table 3 Adverse events of special interest (AESIs) and expected serious adverse events (ESAEs)
AESIs ASAEs (non-reportable)
Metabolic Perioperative
- Hyperglycaemia necessitating treatment or stopping of trial medication
- New onset diabetes necessitating ongoing medical treatment at day 30
of follow-up
- Hyperosmolar hyperglycaemic state
- Re-bleeding into cavity forming ASDH
- Tension pneumocephalus
- Intracerebral haemorrhage
- Residual CSDH exerting mass effect
- Seizures
- Neurological worsening
- Anaesthetic complications
Psychiatric Early
- New onset psychosis - Residual CSDH
- Expansion of contralateral CSDH
- Seizures
Gastric Intermediate and Late
- Upper gastrointestinal side (e.g. heartburn, vomiting)
- Peptic ulceration and gastro-intestinal bleeding
- Recollection of CSDH
- Wound complications
- Surgical site infection and subdural empyema
- Epilepsy
ASDH acute subdural haematoma, CSDH chronic subdural haematoma
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Potential limitations to this study include: reaching
adequate recruitment in this patient population, as it has
been highlighted that researchers can be reluctant to
recruit elderly patients to randomised controlled trials [24];
and ensuring a range of severity of CSDH patients are in-
cluded, as the more severely unwell patients will be unable
to consent for themselves and NOK consent may be per-
ceived as a barrier to recruitment if they are not immedi-
ately available. To help overcome this, IHP consent is an
option and we hope this will be utilised to ensure broad in-
clusion of appropriate patients. Finally, as this study is lim-
ited to the UK, it may be questioned how applicable it is to
other populations; however, we have sought to recruit cen-
tres covering a diverse range of patient demographics and
therefore envisage the results will still be widely applicable.
The trial has successfully completed its feasibility phase
of the first 100 patients and is now into the final phase of
recruitment in 22 neurosurgical centres throughout the
UK. Regular review of unblinded safety data is performed
by the IDMEC, who have reported no concerns thus far.
There is weekly oversight of the trial by a trial manage-
ment group and biannual TSC meetings. Neurosurgical
trainees have also been essential to the ongoing success of
the trial through the British Neurosurgical Trainees Re-
search Collaborative (BNTRC). This is a group that was
founded in 2012 with the aim of encouraging high-quality
multi-centre research within UK neurosurgery [25]. It
promotes the structure where there is a trainee co-
principle investigator (Co-PI) at each centre, helping over-
see local site management and recruitment alongside the
PI and research nurse team. The Dex-CSDH trial offers a
model of how multi-centre trials can be successful in the
UK with support from the wider neurosurgical commu-
nity, including trainee collaboration.
Trial status
Recruitment commenced on 13 August 2015 and is on-
going under protocol version 3 (27 Apr 2017) with 630
patients recruited as of 25 June 2018 across 22 UK sites.
The protocol was written in line with the SPIRIT guide-
lines (see Additional file 1).
Appendix 1
Known drug reactions and interaction with other therapies
– Hepatic microsomal enzyme inducers:
medicines that induce hepatic enzyme cytochrome
P-450 isozyme 3A4 such as phenobarbital, phenytoin,
rifampicin, rifabutin, carbamazepine, primidone and
aminogluethimide may reduce the therapeutic efficacy
of corticosteroids by increasing the rate of metabolism.
– Hepatic microsomal enzyme inhibitors:
medicines that inhibit hepatic enzyme cytochrome
P-450 isozyme 3A4 such as ketoconazole, ciclosporin
or ritonavir may decrease glucocorticoid clearance. A
reduction in corticosteroid dose may be needed to
reduce the risk of adverse effects.
– Antidiabetic agents: corticosteroids may increase
blood glucose levels. Patients may need dosage
adjustment of any concurrent antidiabetic therapy.
– Non-steroidal anti-inflammatory drugs
(NSAIDs): concomitant administration may
increase the risk of gastrointestinal (GI) ulceration.
Aspirin should be used cautiously in conjunction
with corticosteroids in patients with
hypothrombinaemia. The renal clearance of
salicylates is increased by corticosteroids and steroid
withdrawal may result in salicylate intoxication.
Patients should be observed closely for adverse
effects of either medicine.
– Anticoagulants: response to anticoagulants may
be reduced or less often enhanced by
corticosteroids. Close monitoring of the
International Normalized Ratio (INR) or
prothrombin time is recommended.
– Antifungals: the risk of hypokalaemia may be
increased with amphotericin.
– Cardiac glycosides: there is a risk of toxicity if
hypokalaemia occurs due to corticosteroid treatment.
– Mifepristone: the effect of corticosteroids may be
reduced for 3–4 days after mifepristone.
– Vaccines: live vaccines should not be given to
individuals with impaired immune
responsiveness. The antibody response to other
vaccines may be diminished.
– Oestrogens: oestrogens may potentiate the effects
of glucocorticoids. The dose of corticosteroid may
need to be adjusted if oestrogen therapy is
commenced or stopped.
– Somatropin: the growth promoting effect may be
inhibited.
– Sympathomimetics: there is an increased risk of
hypokalaemia if high doses of corticosteroids are
given with high doses of salbutamol, salmeterol,
terbutaline or formoteral.
– Diuretics: excessive potassium loss may be
experienced if glucocorticoids and potassium-
depleting diuretics (such as frusemide and thiazides)
or carbonic anhydrase inhibitors (such as acetazolamide)
are given together.
– Antacids: concurrent use of antacids may decrease
absorption of corticosteroids – efficacy may be
decreased sufficiently to require dosage adjustments
in patients receiving small doses of corticosteroids.
Appendix 2
Adverse event descriptions and details
Contains information regarding;
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– AEs and their evaluation and reporting;
– adverse reactions (ARs);
– SAEs and reactions (SAR);
– Suspected unexpected serious adverse reaction
(SUSAR);
– Reference Safety Information (RSI);
– Expected events;
– Evaluation and reporting of all AEs;
– Pregnancy reporting;
– Toxicity.
Adverse event
Any untoward medical occurrence in a patient or clin-
ical trial patient administered a medicinal product and
which does not necessarily have a causal relationship
with this treatment. An AE can therefore be any un-
favourable and unintended sign (including an abnormal
laboratory finding), symptom or disease temporally as-
sociated with the use of an investigational medicinal
product, whether or not considered related to the in-
vestigational medicinal product.
Recording of AEs must start from the point of in-
formed consent regardless of whether a patient has yet
received a medicinal product.
Adverse reaction to an investigational medicinal
product (AR)
All untoward and unintended responses to an investiga-
tional medicinal product related to any dose adminis-
tered. All AEs judged by either the reporting investigator
or the sponsor as having a reasonable causal relationship
to a medicinal product qualify as ARs. The expression
reasonable causal relationship means to convey in gen-
eral that there is evidence or argument to suggest a
causal relationship.
Serious adverse event or serious adverse reaction
(SAE / SAR)
Any untoward medical occurrence or effect that:
– results in death;
– is life-threatening;
– requires hospitalisation or prolongation of an
existing inpatients´ hospitalisation;
– results in persistent or significant disability or
incapacity;
– is a congenital anomaly or birth defect;
– Is another important medical event.
Life-threatening in the definition of a SAE or SAR
refers to an event in which the patient was at risk of
death at the time of event; it does not refer to an event
which hypothetically might have caused death if it were
more severe. For the purposes of this trial, prolonged
hospitalisation due to delayed transfer will not be con-
sidered a reportable SAE.
Suspected unexpected serious adverse reaction (SUSAR)
A SAR, the nature and severity of which is not con-
sistent with the information set out in the Reference
Safety Information.
Reference Safety Information
The information used for assessing whether an AR is
expected is contained in the Summary of Product Char-
acteristics (SmPC). For this trial the RSI is: section 4.8 –
Undesirable effects, of the Aspen Pharma Trading
Limited, Dexamethasone Tablets SmPC that has been
approved by the MHRA for use in this trial.
Expected events
– Expected AR /SARs
All expected ARs are listed in the latest version of the
reference safety information as specified in the SmPC.
This must be used when making a determination as to
the expectedness of the AR. If the AR meets the criteria
for seriousness it must be reported.
– Expected AE/SAEs
Expected procedural related AEs (if SAEs these are
exempt from expedited reporting). Due to the nature
of the condition and the characteristics of the patient
population, affected individuals can often develop sur-
gical and medical complications. In-hospital death can
occur in approximately 5% of patients with a CSDH.
AEs can be best classified in terms of perioperative,
early, intermediate and late. The following AEs are
‘expected’.
Perioperative
Washout of the CSDH is normally performed through
burr holes and therefore is not always under direct vision.
This can lead to complications such as intracerebral
haematoma (ICH), from inadvertent placement of a cath-
eter during assisted washout or attempted division of
membranes. It may also lead to incomplete washout, espe-
cially if membranes are still intact; therefore, ongoing
CSDH and mass effect postoperatively. During washout,
an acute source of bleeding may be agitated and if not
recognised then a postoperative acute subdural haema-
toma can form in the cavity. The brain does not always fill
the cavity immediately and therefore before closure the
cavity is normally filled with saline to try and eliminate
air. If a large amount of air becomes trapped in the cavity,
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it will lead to pneumocephalus which can be under ten-
sion and cause increased pressure and midline shift. Many
of the patients undergoing this procedure are elderly and
may have multiple co-morbidities; therefore, they are con-
sidered a high anaesthetic risk.
Early
Pneumocephalus can continue to be an issue in the first
few days postoperatively. As the brain re-expands to fill
the space, there is the additional risk of formation or in-
crease in size of a contralateral CSDH. There is also a
risk of seizures following evacuation of the CSDH which
is more likely in patients with any perioperative compli-
cation such as ASDH, ICH and pneumocephalus.
Intermediate
Often a drain is placed initially to help with reduced risk
of recurrence from CSDH; however, this is usually
removed within 48 h. In the week following this, there is
a risk that the CSDH can recollect. There is also a risk
of infection, as with any surgical wound, and if signifi-
cant then this could become a subdural empyema if
there is also a recollection of subdural fluid. Poor wound
healing or dehiscence is a risk, particularly as the
patients are mostly elderly and will have thin skin which
does not heal rapidly. There is an ongoing risk of devel-
oping epilepsy in the first few weeks postoperatively.
Late
The biggest risk of the longer term is of recollection of
the CSDH which may require further surgical treatment.
There is also an ongoing risk of developing late epilepsy.
Evaluation of adverse events
The Sponsor expects that AEs are recorded from the
point of informed consent regardless of whether a pa-
tient has yet received a medicinal product. Individual
AEs should be evaluated by the investigator. This in-
cludes the evaluation of its seriousness, causality and
any relationship between the investigational medicinal
product(s) and/or concomitant therapy and the adverse
event. AEs should only be recorded for the duration of
the patient’s hospital stay.
i. Assessing causality
Definitely: a causal relationship is clinically/biologically
certain. This is therefore an AR.
Probable: A causal relationship is clinically / biologically
highly plausible and there is a plausible time sequence
between onset of the AE and administration of the investi-
gational medicinal product and there is a reasonable
response on withdrawal. This is therefore an AR.
Possible: a causal relationship is clinically / biologically
plausible and there is a plausible time sequence between
onset of the AE and administration of the investigational
medicinal product. This is therefore an AR.
Unlikely: a causal relation is improbable; another
documented cause of the AE is most plausible. This is
therefore an AR.
Unrelated: A causal relationship can be definitely
excluded; another documented cause of the AE is most
plausible. This is therefore an AE.
Unlikely and Unrelated causalities are considered
NOT to be trial drug-related.
Definitely, Probable and Possible causalities are con-
sidered to be trial drug-related. A pre-existing condition
must not be recorded as an AE or reported as an SAE
unless the condition worsens during the trial and meets
the criteria for reporting or recording in the appropriate
section of the CRF.
ii. Assessing severity
Mild: the patient is aware of the event or symptom,
but the event or symptom is easily tolerated.
Moderate: the patient experiences sufficient discomfort
to interfere with or reduce his or her usual level of activity.
Severe: significant impairment of functioning; the pa-
tient is unable to carry out usual activities and / or the
patient’s life is at risk from the event.
iii. Recording of adverse events
This clinical trial is being conducted in a critical
emergency condition. It is important to consider the
natural history of the critical medical event affecting
each patient enrolled, the expected complications of
this event and the relevance of the complications to
the procedures.
All AESIs, including expected systemic and procedure-
related AEs, will be assessed by the Investigator and re-
corded in detail in the medical notes and CRFs. Results
of locally performed clinical laboratory tests (full blood
count, coagulation, biochemical markers) will also be re-
corded in the CRF.
AESIs recorded during the trial will be sent to the
coordinating centre. At the conclusion of the trial, all
AESIs will be subject to statistical analysis, and the
analysis and subsequent conclusions will be included
in the final trial report. AESIs will be review at TSC
meetings. SAEs and SARs must be reported to the
Sponsor.
Reporting adverse events
i. SAEs
Kolias et al. Trials          (2018) 19:670 Page 11 of 14
Each Principal Investigator must report all reportable
SAEs to the Chief Investigator, via the Trial Coordinat-
ing Centre, using the trial-specific SAE form, within 24 h
of their awareness of the event. (For details of SAEs that
are exempt from expedited reporting requirements,
please see Section 12.3.) The Chief Investigator is re-
sponsible for ensuring the assessment of all SAEs for
expectedness and relatedness is completed and the on-
ward notification of all SAEs to the Sponsor immediately
but not > 24 h of first notification. The sponsor has to
keep detailed records of all SAEs reported to them by
the trial team.
The Chief Investigator is also responsible for prompt
reporting of all SAE findings to the competent authority
in each member stage (e.g. the MHRA) if they could:
 adversely affect the health of patients;
 impact on the conduct of the trial;
 alter the risk-to-benefit ratio of the trial;
 alter the competent authority’s authorisation to
continue the trial in accordance with Directive
2001/20/EC.
The completed SAE form can be faxed or emailed. De-
tails of where to report the SAEs can be found on the
Dex-CSDH SAE form and page 2 of the protocol.
ii. Suspected unexpected serious adverse reactions
(SUSARs)
All suspected adverse reactions related to an investiga-
tional medicinal product (the tested IMP and compara-
tors) which occur in the concerned trial, and that are
both unexpected and serious (SUSARs) are patient to
expedited reporting.
The Sponsor delegates the responsibility of notification
of SUSARs to the Chief Investigator. The Chief Investiga-
tor must report all the relevant safety information previ-
ously described, to the:
 Sponsor;
 competent authorities in the member state (e.g. the
MHRA);
 Ethics Committee in the concerned member states.
The Chief Investigator shall inform all investigators
concerned of relevant information about SUSARs that
could adversely affect the safety of patients.
Fatal or life-threatening SUSARs
All parties listed in above must be notified as soon as
possible but no later than seven calendar days after the
trial team and Sponsor has first knowledge of the mini-
mum criteria for expedited reporting. In each case,
relevant follow-up information should be sought and a
report completed as soon as possible. It should be
communicated to all parties within an additional eight
calendar days.
Non-fatal and non-life-threatening SUSARs
All other SUSARs and safety issues must be reported to
all parties listed above as soon as possible but no later
than 15 calendar days after first knowledge of the mini-
mum criteria for expedited reporting. Further relevant
follow-up information should be given as soon as possible.
Minimum criteria for initial expedited reporting of SUSARs
Information on the final description and evaluation of
an AR report may not be available within the required
time frames for reporting. For regulatory purposes, ini-
tial expedited reports should be submitted within the
time limits as soon as the minimum following criteria
are met:
a. a suspected investigational medicinal product;
b. an identifiable patient (e.g. trial patient code number);
c. an AE assessed as serious and unexpected, and for
which there is a reasonable suspected causal
relationship;
d. an identifiable reporting source, and, when available
and applicable:
e. a unique clinical trial identification (EudraCT
number or in case of non-European Community
trial’s the sponsor’s protocol code number);
f. a unique case identification (i.e. sponsor’s case
identification number).
Follow-up reports of SUSARs
In case of incomplete information at the time of initial
reporting, all the appropriate information for an adequate
analysis of causality should be actively sought from the re-
porter or other available sources. Further available relevant
information should be reported as follow-up reports. In
certain cases, it may be appropriate to conduct follow-up of
the long-term outcome of a particular reaction.
Format of the SUSARs reports
Electronic reporting is the expected method for expe-
dited reporting of SUSARs to the competent authority.
The format and content as defined by the competent au-
thority should be adhered to.
Pregnancy reporting
All pregnancies within the trial should be reported to the
Chief Investigator and the Sponsor using the relevant
Pregnancy Reporting Form within 24 h of notification.
Pregnancy reporting would stop threemonths after the
patient’s last dose of IMP for example.
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Pregnancy is not considered an AE unless a negative
or consequential outcome is recorded for the mother or
child/fetus. If the outcome meets the serious criteria,
this would be considered a SAE.
Toxicity: emergency procedures
In the event of suspected toxicity, the trial drug will be
withdrawn. In the event of emergency unblinding, this
will be managed by the appropriate SOP.
Additional file
Additional file 1: SPIRIT checklist. (DOC 123 kb)
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